A substance P receptor (NK1) antagonist enhances the widespread osteoporotic effects of sciatic nerve section.
The long-term effects of sciatic nerve section on bone mineral density (BMD) were studied using dual-energy X-ray absorptiometry (DEXA) in skeletally mature rats. Unilateral sciatic neurectomy caused the rapid loss of cancellous bone in the proximal and distal femur and tibia in the ipsilateral hindlimb and, to a lesser extent, in the contralateral intact hindlimb. The reduction in BMD rapidly progressed for 4 weeks after sciatic section and then gradually stabilized with no evidence of recovery at 12 weeks. The development of osteoporosis in the contralateral intact hindlimb was a novel finding. There was no evidence of disuse in the normal contralateral hindlimb after unilateral sciatic section; grid-crossing activity over a 24-h interval was unchanged and there was no reduction in weight bearing on the contralateral normal hindpaw during the stance phase of ambulation. Unilateral peripheral nerve lesions have well-documented effects on substance P content and function in the corresponding contralateral intact nerve. We hypothesized that after sciatic section a reduction in substance P signaling might contribute to bone loss in the contralateral hindlimb. Daily administration of the substance P receptor (NK1) antagonist LY303870 for 2 weeks caused significant loss of cancellous bone in the denervated and the contralateral hindlimb, evidence that substance P signaling sustained bone density after nerve section. After sciatic neurectomy there was a 33% reduction in sciatic nerve stimulation-evoked extravasation in the contralateral intact hindlimb, indicating transmedian inhibition of substance P signaling after nerve injury. Furthermore, there was a 50% reduction in the substance P content in both tibias after unilateral sciatic section. Collectively, these data support the hypothesis that a widespread reduction in substance P content in bone contributes to the osteoporotic effects of sciatic neurectomy and that residual substance P signaling maintains bone integrity after nerve section in both the denervated and contralateral intact hindlimb.
Kingery
Wade S
WS
Physical Medicine and Rehabilitation Service, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 94304, USA. wkingery@stanford.edu
Offley
Sarah C
SC
Guo
Tian-Zhi
TZ
Davies
M Frances
MF
Clark
J David
JD
Jacobs
Christopher R
CR
D015502:Absorptiometry, Photon; D000367:Age Factors; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects / Q000502:physiology; D003714:Denervation; D018483:Diaphyses / Q000737:chemistry; D005070:Evans Blue / Q000008:administration & dosage / Q000378:metabolism; D005119:Extravasation of Diagnostic and Therapeutic Materials / Q000503:physiopathology; D005269:Femur / Q000737:chemistry; D005528:Foot / Q000502:physiology; D006614:Hindlimb / Q000737:chemistry; D007211:Indoles / Q000494:pharmacology*; D008297:Male; D009043:Motor Activity / Q000502:physiology; D064729:Neurokinin-1 Receptor Antagonists; D010024:Osteoporosis / Q000378:metabolism / Q000503:physiopathology*; D010880:Piperidines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012584:Sciatic Nerve / Q000293:injuries / Q000601:surgery*; D013373:Substance P / Q000032:analysis; D013977:Tibia / Q000737:chemistry; D004561:Transcutaneous Electric Nerve Stimulation; D016474:Weight-Bearing / Q000502:physiology
C096759:1-(N-(2-methoxybenzyl)acetylamino)-3-(1H-indol-3-yl)-2-(N-(2-(4-(piperidin-1-yl)piperidin-1-yl)acetyl)amino)propane; D007211:Indoles; D064729:Neurokinin-1 Receptor Antagonists; D010880:Piperidines; D013373:Substance P; D005070:Evans Blue